Posters
« Back
VALIDATION OF KRISHZYME FACTOR IIa CHROMOGENIC ASSAY FOR TESTING OF TINZAPARIN AND TINZAPARIN INJECTION
EP26519
Poster Title: VALIDATION OF KRISHZYME FACTOR IIa CHROMOGENIC ASSAY FOR TESTING OF TINZAPARIN AND TINZAPARIN INJECTION
Submitted on 05 Oct 2017
Author(s): DR AMITABHA DE
Affiliations: KRISHGEN BIOSYSTEMS
Poster Views: 724
View poster »


Poster Information
Abstract: The inhibitory effect of anti-thrombin III (AT-III) on thrombin,
factor IIa and other coagulation serine proteases in plasma is
increased several thousand-fold by Tinzaparin. This inhibition
accountsfor the anticoagulant effect of Tinzaparin.

The quantitative determination of Tinzaparin levels by the
measurement of their anti-IIa activity is a necessary tool for
monitoring treatment efficacy.

Presence of Tinzaparin catalyzes the reaction between factor IIa and
AT-III. The factor IIa inhibition test is the most useful assay covering
the widest variety of Tinzaparin preparations.

In the assay, the rate of factor IIa inhibition is directly proportional to
the Tinzaparin concentration since both factor IIa and AT-III are in
excess. The residual factor IIa activity is inversely proportional
to the Tinzaparin concentration.

The assay was validated using Tinzaparin Sodium EPRS.

The assay kits manufactured by KRISHGEN BIOSYSTEMS are validated
Chromogenic Assays for the determination of Tinzaparin using anti-lla activity in human plasma successfully met all standard assay-validation parameters and were suitable for use in bioequivalence studies.
Summary: KRISHZYME FIIa Assay kit is a chromogenic assay intended for the
quantitative determination of Tinzaparin / Tinzaparin Sodium in
purified solutions by measurement of factor IIa inhibition activity. The
kit can be used for 100 test reactions as per microtiter plate protocol.
Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters


Genetic Engineering in Male Sterility for Hybrid Variety Development
Abir Hasan Joy

VITVO: Mimicking In Vivo Complexity By The Innovative 3D Model
Olivia Candini1, Giulia Grisendi1, Elisabetta Manuela Foppiani1, Matteo Brogli1, Beatrice Aramini2, Valentina Masciale3, Carlotta Spano1, Tiziana Petrachi4, Elena Veronesi4, Pierfranco Conte5,6, Giorgio Mari1 & Massimo Dominici1,3

Digiceuticals
Helana Lutfi and Shaban Nuredini

Cancer Vaccine, Your T-cell guru: A Bioengineering Approach for Cancer Therapy
Zaween Hanis Bt Mohamad Shamsul, Sam Pei Fong, Chin Chin Liew, Chia Jin Chuah, Turgaa Shini Devaraj, Nur’Awatif Ishak, Sheng Keat Siah, Muhammad Nur Syazwan Md Zin, Kar Cheng Wong

Revolution to Blood Transfusion: The One-Size-Fits-All Artificial Blood
Yi Wen Tay, Geok Fong Ong, Sheh Wen Kuan, Doris Ying Ying Tang, Sweet Mun Wong, Athirah Nurhuda Abdul Razak, Nadia Asyikin Muhammad Rabuan, Nurul Aini Atikah Sidek, Nurain Chow Effandy Chow